Supplementary Digital Content 1, Table: Demographic characteristics and clinical features of the

study population

		Total population <sup>1</sup> n (%), unless otherwise specified
Demographics		
Age – years		$15 \pm 3$
Age	5 to < 10y	7 (11%)
5	10  to  < 19  y	55 (89%)
Sex	Females	26 (42%)
Race/Ethnicity	African American	33 (53%)
	Asian	3 (5%)
	Caucasian	` /
	~ · · · · · · · · · · · · · · · · · · ·	25 (40%)
	Hispanic	1 (2%)
Insurance	Medicaid	15 (24%)
	Private Insurance	47 (76%)
Anthropometrics	(11470)	4 (60/)
Stunting	(HAZ <-2)	4 (6%)
Wasting	(BAZ <-2)	3 (4%)
Overweight	(BAZ >2)	7 (10%)
Clinical Features	Cookers' Discoor	42 (600/)
Disease Type	Crohns' Disease	43 (69%)
Description 6.3	Ulcerative Colitis	19 (31%)
Duration of disease/ years	0	$3 \pm 3$
Duration of disease	0  to  < 2  yrs	22 (36%)
	2  to < 5  yrs	25 (40%)
	5 to < 10 yrs	14 (23%)
	>10 yrs	1 (2%)
Disease location  Prior surgery	Crohns' Disease <sup>2</sup> L1	2 (3%)
	L2 – no upper disease modifier	1 (2%)
	- L4A	2 (3%)
	L3 – no upper disease modifier	30 (48%)
	L3 – L4A	3 (5%)
	– L4B	
		2 (3%)
	E4	3 (5%)
	Ulcerative Colitis <sup>2</sup> E2	4 (6%)
	E4	15 (24%)
	No surgery	44 (71%)
	Anal Surgery	4 (6%)
	Colonic resection	3 (5%)
	Ileocolonic resection	11 (18%)
Disease Activity	Physician Global Assessment Inactive	26 (42%)
•	Mild	20 (33%)
	Moderate	12 (19%)
	Severe	4 (6%)
	Abbreviated PCDAI / Median (25 <sup>th</sup> – 75 <sup>th</sup> )	5 (0 – 20)
	PUCAI/Median (25 <sup>th</sup> – 75 <sup>th</sup> )	
Medical Therapy	rucal/iviediaii (23''' – 73''')	20 (5 – 38)
Current <sup>3</sup>	None	4 (6%)
Current	5-ASA	9 (11%)
	Corticosteroids	
		6 (10%)
	Thiopurines	8 (13%)
	Anti-TNF	44 (71%)
	Methotrexate	3 (5%)
	Folic Acid	1 (2%)
E3	M	10 (160/)
Former <sup>3</sup>	None	10 (16%)
	5-ASA	16 (26%)
	Corticosteroids CDAI: Pediatric Crohn's Disease Activity Index, PUCAI: Pediatric Ulce	47 (75%)

Abbreviations: TI: Terminal Ileum, PCDAI: Pediatric Crohn's Disease Activity Index, PUCAI: Pediatric Ulcerative Colitis Activity Index, ASA: aminosalicylate, TNF: tumor necrosis factor. Note: ¹ Total n=62; ²Paris classification for CD (L1: distal 1/3 ileum ± limited cecal disease, L2: colonic, L3: ileocolonic, L4a (may coexist with L1,L2,L3): upper disease proximal to Ligament of Treitz, L4b (may coexist with L1,L2,L3): upper disease

distal to Ligament of Treitz and proximal to distal 1/3 ileum); <sup>2</sup>Paris classification for UC (E2: left-sided UC distal to splenic flexure, E4: pancolitis proximal to hepatic flexure); <sup>3</sup>some patients were on more than one type of therapy